<DOC>
	<DOCNO>NCT01300299</DOCNO>
	<brief_summary>This trial test feasibility adjuvant chemotherapy stereotactic body radiation therapy early stage non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>STEREOtactic Radiation Chemotherapy Lung Cancer ( STEREO )</brief_title>
	<detailed_description>This study evaluate effect adjuvant chemotherapy patient receive treatment stereotactic radiation early stage lung cancer high risk microscopic metastatic disease . Chemotherapy form cisplatin/docetaxel cisplatin/pemetrexed administer approximately six week Stereotactic Body Radiation Therapy ( SBRT ) . Patients undergo follow clinical evaluation image evaluate treatment response surveillance . A patient population 65 patient require . Enrollment protocol plan multi center involvement state Kentucky part Kentucky Trial Network ( KTN ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Histologically diagnose nonsmall cell lung cancer ( NSCLC , cT1T3 ( &lt; = 5cm ) ( AJCC 7ed ) . The following histology eligible : squamous cell carcinoma , adenocarcinoma , large cell carcinoma , large cell neuroendocrine , nonsmall cell carcinoma otherwise specify ; bronchioloalveolar cell carcinoma subtype NSCLC exclude study assessment multifocal disease spread airways difficult . Required CT chest abdomen contrast unless medically contraindicate ( evaluate lung , mediastinum , liver , adrenal ) Whole Body Positron Emission Tomography ( PET ) stag . An integrate PET/Computed Tomography ( CT ) meet CT PET requirement stag . Images must read trained radiologist perform 8 week prior initiation treatment . PET image must allow adequate visualization primary tumor , drain lymphatics hilar mediastinum , adrenal , skeleton . Note : Per Radiation Therapy Oncology Group ( RTOG ) 0915 inclusion criterion , patient hilar mediastinal lymph node ≤ 1cm abnormal hilar mediastinal uptake PET consider N0 . Patients &gt; 1 cm hilar mediastinal lymph node CT abnormal PET ( include suspicious nondiagnostic uptake ) may still eligible directed tissue biopsy abnormally identify area negative cancer . Deemed medically inoperable experienced thoracic cancer clinician standard lobectomy lymph node sampling/dissection . Inoperability may define utilize number criterion . These include following : Pretreatment Forced Expiratory Volume ( FEV1 ) &lt; 40 % predict Postoperative FEV1 &lt; 30 % predict Severely reduce diffusion capacity Baseline hypoxemia and/or hypercapnia Exercise oxygen consumption &lt; 50 % predict Severe pulmonary hypertension Diabetes mellitus severe end organ damage Severe cerebral , cardiac , peripheral vascular disease Decline surgery evaluation thoracic surgeon Required laboratory value within 2 week chemotherapy initiation Absolute neutrophil count ( ANC ) ≥ 1500 mm3 Platelets ≥ 100,000/mm3 Total Bilirubin ≤ 1.5 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal ( ULN } Serum glutamic pyruvic transaminase ( SGPT ) alanine transaminase ( ALT ) &lt; 5 x upper limit normal ( ULN ) Serum Creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) For patient assign pemetrexed/Cisplatin therapy calculate Creatinine Clearance ( CrCl ) must obtain within 2 week randomization calculate CrCl must &gt; 45mL/min use standard Cockcroft Gault formula Primary lesion size within acceptable criterion Evidence regional metastasis distant metastasis follow appropriate stag Previous radiation chest Chemotherapy within previous five year Previous surgery particular lung tumor Plans concomitant chemotherapy radiation Active systemic pulmonary infection Pregnant lactating female Synchronous primary malignancy prior malignancy past 2 year except invasive malignancy treat definitively patient remain disease free &gt; 3 year life expectancy &gt; 3 year . Previous skin cancer carcinoma situ treat definitively acceptable . Patients assign pemetrexed/cisplatin therapy must NOT squamous cell histology Bronchioloalveolar cell carcinoma exclude assessment multifocal disease spread airways difficult Receipt investigational agent participation investigational drug study within 4 week precede initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>stereotactic</keyword>
</DOC>